<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04425681</url>
  </required_header>
  <id_info>
    <org_study_id>20161BBG70210</org_study_id>
    <nct_id>NCT04425681</nct_id>
  </id_info>
  <brief_title>Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer</brief_title>
  <acronym>OWBLM</acronym>
  <official_title>Phase II Study of Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Nanchang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer&#xD;
      (NSCLC) associated with poor prognosis and rapid deterioration of performance status. The&#xD;
      incidence of LM is increasing, reaching 3.8% in molecularly unselected NSCLC patients, being&#xD;
      more frequent in adenocarcinoma subtype and up to 9% in epidermal growth factor receptor&#xD;
      mutation (EGFRm) lung cancer patients, one-third of patients have concomitant brain&#xD;
      metastasis . This increased incidence may in part be conducive to the increased survival of&#xD;
      patients with EGFRm advanced NSCLC since the introduction of EGFR-tyrosine kinase inhibitions&#xD;
      (TKIs).Currently, no standard therapeutic regimen for LM has been established because of its&#xD;
      rarity and heterogeneity[11], and no approved therapies exists to specifically target LM in&#xD;
      patients with EGFRm NSCLC. TKIs therapy is the first-line treatment of patients with EGFRm of&#xD;
      NSCLC. The leptomeningeal space is a sanctuary site for tumour cells and therapeutic agents&#xD;
      due to the presence of an active blood-brain barrier (BBB), so CSF concentration is an&#xD;
      important factor affecting treatment of LM by TKIs. Standard-dose first- and&#xD;
      second-generation EGFR-TKIs have good systemic efficacy but sub-optimal CNS penetration, as&#xD;
      evidenced by preclinical studies of brain distribution and clinical reports of CSF&#xD;
      penetration[15, 16]. Osimertinib is a third-generation EGFR-TKI, irreversible, oral EGFR-TKI&#xD;
      that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance&#xD;
      mutations, which has demonstrated efficacy in NSCLC CNS metastasis[17-22]. Preclinical, I/II&#xD;
      clinical studies and AURA program (AURA extension, AURA2, AURA17 and AURA3) have shown that&#xD;
      Osimertinib has higher brain permeability than the first- and second-generation.&#xD;
&#xD;
      Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial&#xD;
      growth factor (VEGF), animal studies and autopsy specimens show that VEGF plays an important&#xD;
      role in LM. VEGF and EGFR share many overlapping and parallel downstream pathways. The&#xD;
      biological rationale shows that inhibiting of EGFR and VEGR signaling pathways could improve&#xD;
      the efficacy of antitumor and remove the resistance of EGFR inhibition. Besides, preclinical&#xD;
      researches have shown the similar results. Based on these, numbers of clinical trials have&#xD;
      confirmed that VEGF inhibitors in combination with EGFR-TKI significantly prolong patients'&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II pilot study to evaluate the efficacy and safety of osimertinib with&#xD;
      bevacizumab for LM from EGFRm NSCLC patients. ALL patients were treated with Osimertinib 80mg&#xD;
      oral daily and bevacizumab 7.5mg/kg intravenous every 3 weeks. Study therapy continued until&#xD;
      disease progression, unacceptable adverse event, or withdrawal of consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LM progression-free survival</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Time from LM diagnosis to the first documentation of disease progression or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>ORR, proportion of patients with a best overall response of complete response or partial response (CR+PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LM Overall survival</measure>
    <time_frame>Every 6 weeks, up to 2 years</time_frame>
    <description>LM-OS defined as time from LM diagnosis to death due to any cause or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Every 6 weeks, up to 2 years</time_frame>
    <description>Proportion of patients progression-free by investigator assessment per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Every 3 weeks, up to 2 years</time_frame>
    <description>Number of patients with adverse events (AEs) as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leptomeningeal Metastasis</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR Activating Mutation</condition>
  <arm_group>
    <arm_group_label>Osimertinib With Bevacizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Treatment of LM With osimertinb</description>
    <arm_group_label>Osimertinib With Bevacizumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Treatment of LM With Bevacizumab</description>
    <arm_group_label>Osimertinib With Bevacizumab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age in 18-80 years&#xD;
&#xD;
          -  Pathologically proven NSCLC&#xD;
&#xD;
          -  EGFR mutation , the EGFR status was identified from primary lung tumors using the&#xD;
             amplification refractory mutation system (ARMS) or next-generation sequencing (NGS)&#xD;
             analysis.&#xD;
&#xD;
          -  LM diagnosis was based on the detection of malignant cells in the CSF, the focal or&#xD;
             diffuse enhancement of leptomeninges, and nerve roots or the ependymal surface on&#xD;
             gadolinium-enhanced MRI .&#xD;
&#xD;
          -  No severe abnormal liver and kidney function;&#xD;
&#xD;
          -  No other severe chronic diseases;&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the clinical manifestation of nervous system failure including severe&#xD;
             encephalopathy, grade III-IV white matter lesions confirmed by imaging examination,&#xD;
             moderate or severe coma, and glasgow coma score less than 9 points;&#xD;
&#xD;
          -  Allergic to osimertinib or bevacizumab&#xD;
&#xD;
          -  Any of the following: Pregnant women ;Nursing women ;Men or women of childbearing&#xD;
             potential who are unwilling to employ adequate contraception&#xD;
&#xD;
          -  History of myocardial infarction or other evidence of arterial thrombotic disease&#xD;
             (angina), symptomatic congestive heart failure (New York Heart Association ≥ grade 2),&#xD;
             unstable angina pectoris, or cardiac arrhythmia; Note: allowed only if patient has no&#xD;
             evidence of active disease for at least 6 months prior to randomization;&#xD;
&#xD;
          -  History of cerebral vascular accident (CVA) or transient ischemic attack (TIA)≤ 6&#xD;
             months prior to randomization&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  History of hemoptysis da≥ grade 2 (defined as bright red blood of at least 2.5 mL) ≤3&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Leukocytes below 2*10^9/L, neutrophils below 1*10^9/L; platelets below 50*10^9/L;&#xD;
&#xD;
          -  Had major surgery within 60 days;&#xD;
&#xD;
          -  History of arteriovenous thrombosis&#xD;
&#xD;
          -  Gastrointestinal perforator in the past 6 months&#xD;
&#xD;
          -  Inadequately controlled hypertension (systolic blood pressure of &gt; 150 mmHg or&#xD;
             diastolic pressure &gt; 100 mmHg on anti-hypertensive medications); Note: history of&#xD;
             hypertensive crisis or hypertensive encephalopathy not allowed&#xD;
&#xD;
          -  Grade 4 proteinuria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liu Anwen, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Nanchang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Anwen, Phd</last_name>
    <phone>+8613767120022</phone>
    <email>awliu666@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huang s Shu, MD,PhD</last_name>
    <phone>+8607918626884</phone>
    <email>xiaoshumenfan@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Afiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anwen Liu, MD</last_name>
      <phone>+8613767120022</phone>
      <email>awliu666@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.</citation>
    <PMID>31751012</PMID>
  </results_reference>
  <results_reference>
    <citation>Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.</citation>
    <PMID>31108248</PMID>
  </results_reference>
  <results_reference>
    <citation>Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.</citation>
    <PMID>31085043</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.</citation>
    <PMID>30059262</PMID>
  </results_reference>
  <results_reference>
    <citation>Taillibert S, Chamberlain MC. Leptomeningeal metastasis. Handb Clin Neurol. 2018;149:169-204. doi: 10.1016/B978-0-12-811161-1.00013-X.</citation>
    <PMID>29307353</PMID>
  </results_reference>
  <results_reference>
    <citation>Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.</citation>
    <PMID>29151359</PMID>
  </results_reference>
  <results_reference>
    <citation>Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. No abstract available.</citation>
    <PMID>29782558</PMID>
  </results_reference>
  <results_reference>
    <citation>Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.</citation>
    <PMID>24893891</PMID>
  </results_reference>
  <results_reference>
    <citation>Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Yamane H, Kamei H, Kiura K, Tanimoto M. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012 Jul;77(1):134-9. doi: 10.1016/j.lungcan.2012.03.002. Epub 2012 Apr 7.</citation>
    <PMID>22487432</PMID>
  </results_reference>
  <results_reference>
    <citation>Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404.</citation>
    <PMID>17374728</PMID>
  </results_reference>
  <results_reference>
    <citation>De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008 Mar;214(3):559-67. doi: 10.1002/jcp.21260.</citation>
    <PMID>17894407</PMID>
  </results_reference>
  <results_reference>
    <citation>Lv Y, Mu N, Ma C, Jiang R, Wu Q, Li J, Wang B, Sun L. Detection value of tumor cells in cerebrospinal fluid in the diagnosis of meningeal metastasis from lung cancer by immuno-FISH technology. Oncol Lett. 2016 Dec;12(6):5080-5084. doi: 10.3892/ol.2016.5314. Epub 2016 Oct 25.</citation>
    <PMID>28105214</PMID>
  </results_reference>
  <results_reference>
    <citation>Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Target Oncol. 2018 Jun;13(3):269-285. doi: 10.1007/s11523-018-0566-1. Erratum In: Target Oncol. 2018 Oct;13(5):667.</citation>
    <PMID>29700687</PMID>
  </results_reference>
  <results_reference>
    <citation>Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.</citation>
    <PMID>28627678</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leptomeningeal metastasis</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>EGFR Activating Mutation</keyword>
  <keyword>Osimertinib</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04425681
org study id: 20161BBG70210
nct id: NCT04425681
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer
      (NSCLC) associated with poor prognosis and rapid deterioration of performance status. The
      incidence of LM is increasing, reaching 3.8% in molecularly unselected NSCLC patients, being
      more frequent in adenocarcinoma subtype and up to 9% in epidermal growth factor receptor
      mutation (EGFRm) lung cancer patients, one-third of patients have concomitant brain
      metastasis . This increased incidence may in part be conducive to the increased survival of
      patients with EGFRm advanced NSCLC since the introduction of EGFR-tyrosine kinase inhibitions
      (TKIs).Currently, no standard therapeutic regimen for LM has been established because of its
      rarity and heterogeneity[11], and no approved therapies exists to specifically target LM in
      patients with EGFRm NSCLC. TKIs therapy is the first-line treatment of patients with EGFRm of
      NSCLC. The leptomeningeal space is a sanctuary site for tumour cells and therapeutic agents
      due to the presence of an active blood-brain barrier (BBB), so CSF concentration is an
      important factor affecting treatment of LM by TKIs. Standard-dose first- and
      second-generation EGFR-TKIs have good systemic efficacy but sub-optimal CNS penetration, as
      evidenced by preclinical studies of brain distribution and clinical reports of CSF
      penetration[15, 16]. Osimertinib is a third-generation EGFR-TKI, irreversible, oral EGFR-TKI
      that potently and selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance
      mutations, which has demonstrated efficacy in NSCLC CNS metastasis[17-22]. Preclinical, I/II
      clinical studies and AURA program (AURA extension, AURA2, AURA17 and AURA3) have shown that
      Osimertinib has higher brain permeability than the first- and second-generation.

      Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial
      growth factor (VEGF), animal studies and autopsy specimens show that VEGF plays an important
      role in LM. VEGF and EGFR share many overlapping and parallel downstream pathways. The
      biological rationale shows that inhibiting of EGFR and VEGR signaling pathways could improve
      the efficacy of antitumor and remove the resistance of EGFR inhibition. Besides, preclinical
      researches have shown the similar results. Based on these, numbers of clinical trials have
      confirmed that VEGF inhibitors in combination with EGFR-TKI significantly prolong patients'
      survival.
This is a phase II pilot study to evaluate the efficacy and safety of osimertinib with
      bevacizumab for LM from EGFRm NSCLC patients. ALL patients were treated with Osimertinib 80mg
      oral daily and bevacizumab 7.5mg/kg intravenous every 3 weeks. Study therapy continued until
      disease progression, unacceptable adverse event, or withdrawal of consent.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: LM progression-free survival
time frame: up to 1 year
description: Time from LM diagnosis to the first documentation of disease progression or death
measure: Objective Response Rate
time frame: up to 1 year
description: ORR, proportion of patients with a best overall response of complete response or partial response (CR+PR)
measure: LM Overall survival
time frame: Every 6 weeks, up to 2 years
description: LM-OS defined as time from LM diagnosis to death due to any cause or last follow-up
measure: progression-free survival
time frame: Every 6 weeks, up to 2 years
description: Proportion of patients progression-free by investigator assessment per RECIST v1.1
measure: adverse events
time frame: Every 3 weeks, up to 2 years
description: Number of patients with adverse events (AEs) as a measure of safety and tolerability
arm group label: Osimertinib With Bevacizumab group
arm group type: Experimental
description: Osimertinib 80 mg oral daily; and bevacizumab 7.5 mg/kg intravenous every 3 weeks
intervention type: Drug
intervention name: Osimertinib
description: Treatment of LM With osimertinb
arm group label: Osimertinib With Bevacizumab group
intervention type: Drug
intervention name: Bevacizumab
description: Treatment of LM With Bevacizumab
arm group label: Osimertinib With Bevacizumab group
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Liu Anwen, Phd
role: Study Director
affiliation: Second Affiliated Hospital of Nanchang University
last name: Liu Anwen, Phd
phone: +8613767120022
email: awliu666@163.com
last name: Huang s Shu, MD,PhD
phone: +8607918626884
email: xiaoshumenfan@126.com
facility: 
status: Recruiting
contact: 
country: China
citation: Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
PMID: 31751012
citation: Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.
PMID: 31108248
citation: Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.
PMID: 31085043
citation: Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.
PMID: 30059262
citation: Taillibert S, Chamberlain MC. Leptomeningeal metastasis. Handb Clin Neurol. 2018;149:169-204. doi: 10.1016/B978-0-12-811161-1.00013-X.
PMID: 29307353
citation: Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
PMID: 29151359
citation: Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M. Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. No abstract available.
PMID: 29782558
citation: Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.
PMID: 24893891
citation: Umemura S, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Yamane H, Kamei H, Kiura K, Tanimoto M. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer. 2012 Jul;77(1):134-9. doi: 10.1016/j.lungcan.2012.03.002. Epub 2012 Apr 7.
PMID: 22487432
citation: Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404.
PMID: 17374728
citation: De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008 Mar;214(3):559-67. doi: 10.1002/jcp.21260.
PMID: 17894407
citation: Lv Y, Mu N, Ma C, Jiang R, Wu Q, Li J, Wang B, Sun L. Detection value of tumor cells in cerebrospinal fluid in the diagnosis of meningeal metastasis from lung cancer by immuno-FISH technology. Oncol Lett. 2016 Dec;12(6):5080-5084. doi: 10.3892/ol.2016.5314. Epub 2016 Oct 25.
PMID: 28105214
citation: Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Target Oncol. 2018 Jun;13(3):269-285. doi: 10.1007/s11523-018-0566-1. Erratum In: Target Oncol. 2018 Oct;13(5):667.
PMID: 29700687
citation: Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.
PMID: 28627678
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Neoplasm Metastasis
mesh term: Meningeal Carcinomatosis
mesh term: Bevacizumab
mesh term: Osimertinib
sharing ipd: No